This study is the first to systematically integrate three distinct classes of drugs—SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas—and compare their efficacy and safety in patients with T2DM and heart failure through a network meta-analysis. Here, GLP1R is linked to heart failure.